Transcription of Scientific guidelines with SmPC recommendations
{{id}} {{{paragraph}}}
30 Churchill Place Canary Wharf London E14 5EU United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 25 January 2017 EMA/813125/2012 rev. 4 Scientific guidelines with SmPC recommendations Table of contents Table of contents .. 1 1. Clinical efficacy and safety .. 1 2. Quality and biological .. 4 3. Non-clinical .. 5 Note: the tables below only include adopted Scientific guidelines which refer specifically to the SmPC. For complete information on Scientific guidelines , please refer to the European Medicines Agency website ( ). guidelines under review are marked with an * 1. Clinical efficacy and safety guidelines Reference to specific SmPC section(s) Advanced therapies Guideline on xenogeneic cell-based medicinal products Reflection paper on the use of pharmacogenetics in the pharmacokinetic evaluation of medicinal products , , , , , , Anti-infectives for systemic use CHMP position paper on thiomersal implementation of the warning statement relating to sensitisation , , CHMP guideline on clinical evaluation of new vaccines.
Scientific guidelines with SmPC recommendations EMA/813125/2012 Page 2/5 Guidelines Reference to specific SmPC section(s) treatment of HIV infection
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
Intravenous Immunoglobulin IVIG, IVIg, Patients, IVIG is the transmissible, CIDP Treatment With Subcutaneous Immunoglobulin IgPro20, Myasthenia Gravis, Immune Globulin, Aetna Precertification, Precertification, Coagulation in pregnancy, Johnson Syndrome and Toxic Epidermal, Johnson Syndrome and Toxic Epidermal Necrolysis